Armata Pharmaceuticals, Inc. · AMEX:ARMP
Armata Pharmaceuticals — H.C. Wainwright 27th Annual Global Investment Conference (September 2025)
29 slides from Armata Pharmaceuticals's conference presentation, Sep 11, 2025
Slide 1: Corporate Presentation
Corporate Presentation Deborah Birx, M.D. Chief Executive Officer H.C. Wainwright 27 th Annual Global Investment Conference September 10, 2025 NYSE American: ARMP
Slide 2: Forward-looking statements
2 This presentation contains “forward - looking” statements that involve risks, uncertainties and assumptions . If the risks or uncertainties materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward - looking statements . All s
Slide 3: Phages Are a Novel Biologic Anti-Infective with Distinct MOA from Antibiotics
3 Phages Are a Novel Biologic Anti - Infective with Distinct MOA from Antibiotics and Significant Advantages for the Fight Against AMR PHAGE ADVANTAGES How Phages Kill Bacteria Novel therapeutic approach addresses increasing antibiotic - induced microbial resistance Phage activity independent of ant
Slide 4: State of Phage Development and Approval
4 State of Phage Development and Approval PHAGE ADVANTAGES The phage field has focused on compassionate use cases and individualized medicine. What is urgently needed are definitive pivotal trials that clearly address: • Role of phage therapy as an alternative or augmentation of antibiotics to preve
Slide 5: Consistent Progress on Clinical Programs for Critical Indications
5 Consistent Progress on Clinical Programs for Critical Indications Phage Evaluation via Randomized - Controlled Clinical Trials SWARM - P.a. NCT04596319 ; diSArm NCT05184764 ; Tail wind NCT05616221 Department of Defense (DoD) award received through the Medical Technology Enterprise Consortium (MTEC
Slide 6: Delivered on Value-Inflection Milestones Positions Both Programs For Pivotal Studies
6 Delivered on Value - Inflection Milestones Positions Both Programs For Pivotal Studies CF: cystic fibrosis; NCFB: non - CF bronchiectasis; SAB: S. aureus bacteremia AP - PA02 CF Ph1b/2a topline data NCFB Ph2 first patient dosed NCFB Ph2 enrollment completion NCFB Ph2 topline data (4Q24) AP - SA02
Slide 7: In-House Infrastructure Allows for Commercial Scalability and Alternate Revenue Streams
7 In - House Infrastructure Allows for Commercial Scalability and Alternate Revenue Streams State - of - the - art cGMP manufacturing facility • 10,000 square foot purpose - built facility in Los Angeles, California • Essential infrastructure for phage production - Two independent production lines w
Slide 8: Complicated Bacteremia Staphylococcus aureus Program (AP-SA02)
Complicated Bacteremia Staphylococcus aureus Program (AP - SA02)
Slide 9: Our Opportunity: The Problem SAB and the Solution AP-SA02
9 • Complicated Staphylococcus aureus bacteremia (SAB) is a serious bloodstream infection with ~54,000 annual U.S. - based hospital episodes • Prognosis with complicated SAB is poor , including long - term hospitalization, increased healthcare resource utilization, and risk of mortality • Currently
Slide 10: Bacteremia Phase 1b/2a diSArm Study Design
10 Bacteremia Phase 1b/2a “diSArm” Study Design Primary Study Endpoints in Intent - to - Treat (ITT) Population ITT: All subjects that received BAT and at least one d ose of AP - SA02 or Placebo (BAT only) Phase 1b: Safety and tolerability of multiple intravenous (IV) doses of AP - SA02 Phase 2a: Cl
Slide 11: Phase II Trial Demographics, Site of Infection
11 Phase II Trial Demographics, Site of Infection
Slide 12: Phase II Trial Antibiotics Used, Clinical Trends
12 Phase II Trial Antibiotics Used, Clinical Trends
Slide 13: Adverse Event Summary
13 Phase 2a Complicated SAB Phase 1b Uncomplicated SAB Placebo (N=13) AP - SA02 (N=29) Placebo (N=2) AP - SA02 (N=6) n (%) n (%) n (%) n (%) 12 (92.3) 19 (65.5) 2 (100.0) 6 (100.0) Any adverse events (AEs) 10 (76.9) 17 (58.6) 2 (100.0) 6 (100.0) Any treatment - emergent AEs (TEAEs) 1 0 (0.0) 1 (3.4)
Slide 14: No Serious AEs Related to AP-SA02
14 No Serious AEs Related to AP - SA02 Only 2 Subjects With AEs Possibly Related to AP - SA02 Phase 2a Complicated SAB Phase 1b Uncomplicated SAB Placebo (N=13) AP - SA02 (N=29) Placebo (N=2) AP - SA02 (N=6) System Organ Class n (%) n (%) n (%) n (%) Preferred Term * 0 (0.0) 1 (3.4) 0 (0.0) 1 (16.7)
Slide 15: AP-SA02 Improved Clinical Outcome in ITT Population at TOC (Day 12)
15 BAT alone (n=12) BAT + AP-SA02 (n=24) 0 10 20 30 40 50 60 70 80 90 100 P e r c e n t *p = 0.047 AP - SA02 Improved Clinical Outcome in ITT Population at TOC for AP - SA02 (Day 12) Significantly Improved Responder Rate (88%) Assessed by Blinded PI • Improved responder rate in AP - SA02 treated sub
Slide 16: AP-SA02 Improved Clinical Outcome At All Timepoints
16 AP - SA02 Improved Clinical Outcome in ITT Population At All Timepoints 100% Clinical Response in AP - SA02 Treated Subjects at TOC BAT and at EOS Data are preliminary and remains subject to further review and quality control Clinical Outcome at TOC BAT and at EOS • Statistically significant incr
Slide 17: All Subjects With MRSA That Received AP-SA02 Cleared Infection
17 All Subjects With MRSA That Received AP - SA02 Cleared Infection, No Evidence of Relapse AP - SA02 Effective Against Both MRSA and MSSA Clinical Outcome Assessed by Blinded PI MRSA Infected Subjects • 100% of AP - SA02 treated subjects clinically responded regardless of MSSA or MRSA infection • A
Slide 18: Summary of Clinical Findings
18 Summary of Clinical Findings P I ( n = 2 4 ) P I ( n = 1 2 ) A C ( n = 2 4 ) A C ( n = 1 2 ) P I ( n = 2 1 ) P I ( n = 8 ) A C ( n = 2 1 ) A C ( n = 9 ) P I ( n = 2 1 ) P I ( n = 8 ) A C ( n = 2 0 ) A C ( n = 8 ) 0 20 40 60 80 100 Clinical Response P e r c e n t AP-SA02 Placebo TOC (Day 12)* EOS*
Slide 19: Faster Decline of Key Biomarkers in AP-SA02 Treated Subjects
19 Faster Decline of Key Biomarkers in AP - SA02 Treated Subjects: Supports Clinical Outcome Mean CRP Levels Reached Normal by Day 12^; Remains Elevated in Subjects On BAT Alone C - reactive Protein (CRP) • General indicator of Inflammation • Predictor of mortality and complications in bacteremia 1
Slide 20: Proposed Superiority Pivotal Trial Design
20 Proposed Superiority Pivotal Trial Design • Primary endpoint clinical response at day 60 (TOC) • Secondary endpoints • Clinical response at day 14 (TOC) • Time to hospital discharge • Microbiologic eradication at time 60 and 14 days • All Cause Mortality • Sample size: 406 total (203 per group) t
Slide 21: CF and NCFB Pseudomonas aeruginosa Program (AP-PA02)
Cystic Fibrosis (CF) Non - CF Bronchiectasis (NCFB) Pseudomonas aeruginosa Program (AP - PA02)
Slide 22: NCFB Phase 2 Tailwind Study: Completed 3Q24
22 NCFB Phase 2 Tail wind Study: Completed 3Q24 Evaluated AP - PA02 as Monotherapy and in Combination with Inhaled Antibiotics ▪ AP - PA02 nebulized q12h x 10 days ▪ Subjects dosed at home ▪ Started with highest dose from CF study (increased dose 2X after lead in) ▪ Evaluated AP - PA02 exposures in
Slide 23: Post Hoc P. aeruginosa Efficacy Data
23 POST HOC P. aeruginosa Efficacy Data ITT Population Analysis - All 48 Subjects * Non - parametric, unpaired t - T est ** Paired t - Test Significant difference in the treated group between baseline and Days 10, 11, 17, and 24 but not at any timepoint in placebo Change in Pa density from Baseline:
Slide 24: Corporate Summary
Corporate Summary
Slide 25: Management Leadership and Board of Directors
25 Management Leadership and Board of Directors Diverse Public Company Drug Development Expertise Deborah Birx, MD CEO Peter Hubbard, MBA VP, Operations Bhaumik Patel Quality Assurance Pierre Kyme, PhD CBO Robin Kramer, Chair Deborah Birx, MD Jules Haimovitz Odysseas Kostas, MD Board of Directors Jo
Slide 26: Strong Relationships with Partners Supporting Development of Phage Therapy
26 Strong Relationships with Partners with Demonstrated Interest in Supporting Development of Phage Therapy LEADERSHIP AND PARTNERS Armata Partnerships $5M Therapeutics Development Award • Support Ph1b/2a SWARM - P.a. study • All milestones achieved $3M equity investment (4Q21) $26.2M OTA with DoD t
Slide 27: Funding and Capitalization
27 Funding and Capitalization Cash Position • $4.3 million in unrestricted cash and cash equivalents at June 30, 2025* ― Not inclusive of $15M received on August 11, 2025 Financing History • Q1 2020: $25M private placement of common stock and warrants with Innoviva, Inc. • Q1 2021: $20M private plac
Slide 28: Armata has Multiple Sources of Long-term Value Going Forward
28 Armata has Multiple Sources of Long - term Value Going Forward AP - SA02 Bacteremia Program is the Key Driver to Unlock Growth Groundbreaking clinical results addressing high unmet need in Staph aureus bacteremia Statistically significant efficacy improvement over standard of care 100% clinical r
Slide 29: Purposeful, Precise, Powerful
PURPOSEFUL @ PRECISE @ POWERFUL www.armtapharma.com